title: Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
authors.affiliation: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Jerbai Wadia Road, Parel, Mumbai, Maharashtra, India, 400012. drsanb@yahoo.com.
authors.forename: Sandip
authors.initials: S
authors.lastname: Basu
authors.affiliation: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Jerbai Wadia Road, Parel, Mumbai, Maharashtra, India, 400012.
authors.forename: Ashwini
authors.initials: A
authors.lastname: Kalshetty
mesh_terms: D002986:Clinical Trials as Topic; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D000072078:Positron Emission Tomography Computed Tomography; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D047428:Protein Kinase Inhibitors; D019788:Fluorodeoxyglucose F18; D011505:Protein-Tyrosine Kinases